Sygnature Discovery Unveils £1M Upgrade to High-Throughput Chemistry Platform

• Sygnature Discovery has completed a £1 million upgrade to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure.

• The enhancements include doubled synthesis and purification capacity and the integration of supercritical fluid chromatography (SFC).

Sygnature Discovery, an integrated drug discovery contract research organisation (CRO), has announced the completion of a £1 million enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure.

The investment has resulted in a doubling of synthesis and purification capacity, providing faster access to high-quality compounds for customers. The upgraded HTC platform is designed to accelerate compound delivery, enabling quicker decision-making and supporting progress toward clinical development.

A key feature of the upgrade is the integration of supercritical fluid chromatography (SFC), a purification method that, while increasingly common, remains rare in HTC platforms. With both reverse-phase and SFC options now available, Sygnature offers customers increased flexibility and the ability to optimise purification conditions.

The newly enhanced facilities are set to become fully operational from August. The development forms part of Sygnature’s broader growth strategy to support drug discovery clients through advanced technology platforms.

Geraint Jones, Director of Chemistry at Sygnature Discovery, said: “Our successful track record over the past 20 years on client projects demonstrates our ability to validate robust syntheses and utilize automated processes to deliver high-quality science quickly and efficiently.”